(Q24561822)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15310558%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15310558%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

0 references

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15310558%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Carl E Clarke

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15310558%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Richard Gray

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15310558%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Natalie J Ives

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15310558%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Joanna Marro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15310558%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Carl Counsell

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15310558%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Angus Macleod

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15310558%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Keith Wheatley

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15310558%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

language of work or name

English

0 references

publication date

13 August 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15310558%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15310558%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

329

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15310558%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

7466

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15310558%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

593

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15310558%20AND%20SRC:MED&resulttype=core&format=json

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

31 December 2019

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516655

Statistical aspects of the analysis of data from retrospective studies of disease

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516655

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516655

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516655

Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Formal systematic review of data on patients in all relevant trials is required

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516655

Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential i

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516655

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516655

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516655

The statistical basis of meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516655

Identifying relevant studies for systematic reviews

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516655

Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516655

The effect of deprenyl and levodopa on the progression of Parkinson's disease

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516655

Selegiline as initial treatment in de novo parkinsonian patients

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516655

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516655

Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516655

Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516655

Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516655

Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinsonism.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516655

Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516655

Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial

28 November 2018

1 reference

12 December 2020

Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group

1 reference

12 December 2020

DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group

1 reference

12 December 2020

Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study.

1 reference

12 December 2020

A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group

1 reference

12 December 2020

MAO-B inhibitors for the treatment of Parkinson's disease

1 reference

12 December 2020

SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa

1 reference

12 December 2020

Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Selegiline in Parkinson's disease

1 reference

12 December 2020

A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Parkinson Study Group

1 reference

12 December 2020

Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group.

1 reference

12 December 2020

Lisuride plus selegiline in the treatment of early Parkinson's disease

1 reference

12 December 2020

Delayed development of symptomatic improvement by (−)-deprenyl in Parkinson's disease

1 reference

12 December 2020

Effect of deprenyl on the progression of disability in early Parkinson's disease

1 reference

12 December 2020

10.1136/BMJ.38184.606169.AE

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qpmvqooo65abnmozqxzx6dpf4e

30 July 2022

release_qpmvqooo65abnmozqxzx6dpf4e

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qpmvqooo65abnmozqxzx6dpf4e

30 July 2022

OpenCitations bibliographic resource ID

2509787

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

https://api.fatcat.wiki/v0/release/qpmvqooo65abnmozqxzx6dpf4e

30 July 2022

https://api.fatcat.wiki/v0/release/qpmvqooo65abnmozqxzx6dpf4e

1 reference

30 July 2022